Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 629-719-3 | CAS number: 1219010-04-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
For each endpoint bacterial mutagenicity, mammalian mutagenicity and mammalian clastogenicity one GLP compliant study is available on the basis of testing with N-(hydrogenated tallow alkyl) trimethylenediamine itself or from cross-reading from N-oleyl trimethylenediamine.Allin vitrogenotoxicity studies for this endpoint addressing bacterial mutagenicity, mammalian mutagenicity and mammalian clastogenicity were all negative within the range of the Diamine category. Lack of genotoxic properties of alkyl-diamines was further confirmed in an in vivo micronucleus study with Coco-diamine.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 2008-05-14 - 2008-09-23
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- histidine operon (his)
- Species / strain / cell type:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- liver rat S9-mix (induced with ß-naphthoflavone and phenobarbital)
- Test concentrations with justification for top dose:
- Experiment 1:
0.00010, 0.000316, 0.00100, 0.00316, 0.0100, 0.0316 and 0.1 µL/plate
Experiment 2:
0.000158, 0.00050, 0.00158, 0.0050, 0.0158, 0.05 and 0.1 µL/plate (TA 98, TA 100, TA 1537, E. coli WP2 uvrA)
0.000050, 0.000158, 0.00050, 0.00158, 0.0050, 0.0158 and 0.05 µL/plate (TA 1535) - Vehicle / solvent:
- Ethanol
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 10 µg/plate sodium azide (NaN3) (TA 100, TA 1535); 10 µg/plate (TA 98) and 40 µg/plate (TA 1537) 4-nitro-o-phenylene-diamine (4-NOPD); 1 µL/plate methylmethanesulfonate (MMS) (E. coli); 2.5 µg/plate for TA 98, 100, 1535, 1537 and 10 µg/plate for E. coli
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Exposure duration: 48 hours
NUMBER OF REPLICATIONS: triplicates in 2 experiments
DETERMINATION OF CYTOTOXICITY
- Method: background lawn or reduction in the number of revertants down to a mutation factor of approximately ≤ 0.5 in relation to the solvent control
ADDITIONAL INFORMATION
- Data recording:
The colonies were counted using a ProtoCOL counter (Meintrup DWS Laborgeräte GmbH. If precipitation of the test item precluded automatic counting the revertant colonies were counted by hand. In addition, tester strains with low spontaneous mutation frequency like TA 1535 and TA 1537 were counted manually. - Evaluation criteria:
- Criteria of validity:
A test is considered acceptable if for each strain:
1. the bacteria demonstrate their typical response to ampicillin (TA 98, TA 100)
2. the control plates with and without metabolic activation are within the following ranges (mean values of the spontaneous reversion frequency are within the historical control data range):
TA 98: 18 - 54 (-S9) and 18 - 71 (+S9)
TA 100: 75 - 167 (-S9) and 81 - 168 (+S9)
TA 1535: 5 - 29 (-S9) and 6 - 31 (+S9)
TA 1537: 5 - 30 (-S9) and 6 - 36 (+S9)
E. coli WP2 uvrA: 35 - 92 (-S9) and 37 - 101 (+S9)
3. corresponding background growth on both negative control and test plates is observed
4. the positive controls show a distinct enhancement of revertant rates over the control plate
Evaluation of mutagenicity:
The mutation factor is calculated by dividing the mean value of the revertant counts through the mean values of the solvent control (the exact and not the rounded values are used for calculation).
A test item is considered as mutagenic if:
1. a clear and dose-related increase in the number of revertants occurs and/or
2. a biologically relevant positive response for at least one of the dose groups occurs
in at least one tester strain with or without metabolic activation.
A biologically relevant increase is described as follows:
1. if in tester strains Ta 100 and E. coli WP2 uvrA the number of reversions is at least twice as high
2. if in tester strains TA 1535, TA 1537 and TA 98 the number of reversions is at least three times higher
as compared to the reversion rate of the solvent control. - Statistics:
- no data
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 0.00316 - 0.1 µL/plate (details in "Additional information on results")
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: No precipitation of the test item was observed in any of the 5 tester strains used in experiment 1 and 2 with and without metabolic activation.
RANGE-FINDING/SCREENING STUDIES:
The toxicity of the test item was determined with tester strain TA 98 and TA 100 in a pre-experiment. Eight concentrations were tested for toxicity and induction of mutations with three plates each. The experimental conditions in this pre-experiment were the same as for the main experiment.
Toxicity may be detected by a clearing or rather diminution of the background lawn or a reduetion in the number of revertants down to a mutation factor of approximately ≤ 0.5 in relation to the solvent control.
The test item was tested in the pre-experiment at the following concentrations:
0.00316, 0.0100, 0.0316, 0.100, 0.316, 1.0, 2.5 and 5.0 µL/plate
Based on the pre-experiment results the following concentrations were used for the main experiments:
Experiment 1: 0.0001 - 0.1 µL/plate and Experiment 2: 0.000158 - 0.1 µL/plate (TA 98, TA 100, TA 1537, E. coli WP2 uvrA) and 0.00005 - 0.05 µL/plate (TA 1535)
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Cytotoxic effects in experiment 1:
at 0.00316 µL/plate (-S9) and 0.0316 µL/plate (+S9) (TA 98 and TA 100);
at 0.010 µL/plate (-S9) and 0.1 µL/plate (+S9) (TA 1535);
at 0.01 µL/plate (-S9) and 0.0316 µL/plate (+S9) (TA 1537);
at 0.0316 µL/plate (-S9) and 0.1 µL/plate (+S9) (E. coli WP2 uvrA)
Cytotoxic effects in experiment 2:
at 0.0050 µL/plate (-S9) and 0.05 µL/plate (+S9) (TA 98, TA 100, TA 1535, TA 1537);
at 0.0158 µL/plate (-S9) and 0.1 µL/plate (+S9) (E. coli WP2 uvrA) - Remarks on result:
- other: strain/cell type: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvrA
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
In conclusion, it can be stated that during the described mutagenicity test and under the experimental conditions reported, N-Oleyl-1,3- diaminopropane did not cause gene mutations by base pair changes or frameshifts in the genome of the tester strains used.
Therefore, N-Oleyl-1,3-diaminopropane is considered to be non-mutagenic in this bacterial reverse mutation assay. - Executive summary:
The test item N-Oleyl-1,3-diaminopropane was investigated for its potential to induce gene mutations according to the OECD guideline 471.
In two independent plate incorporation tests using Salmonella typhimurium strains TA 98, TA 100, TA 1535, TA 1537 and tester strain E. coli WP2 uvrA several concentrations of the test item were used. Each assay was conducted with and without metabolic activation. The concentrations, including the controls, were tested in triplicates. The following concentrations of the test item were prepared and used in the experiments:
Experiment 1:
0.00010, 0.000316, 0.00100, 0.00316, 0.0100, 0.0316 and 0.1 µL/plate
Experiment 2:
0.000158, 0.00050, 0.00158, 0.0050, 0.0158, 0.05 and 0.1 µL/plate (TA 98, TA 100, TA 1537, E. coli WP2 uvrA) and
0.000050, 0.000158, 0.00050, 0.00158, 0.0050, 0.0158 and 0.05 µL/plate (TA 1535).
No precipitation of the test item was observed in any of the five tester strains used in experiment 1 and 2 with and without metabolic activation.
Toxic effects of the test item were noted in all tester strains evaluated in experiment 1 and 2.
In experiment 1 toxic effects of the test item were observed in tester strains TA 98 and TA 100 at doses of 0.00316 µL/plate and higher (without metabolic activation) and at doses of 0.0316 µL/plate and higher (with metabolic activation). In tester strain TA 1535 toxic effects of the test item were noted at doses of 0.01 µL/plate and higher (without metabolic activation) and at a dose of 0.1 µL/plate (with metabolic activation). In tester strain TA 1537 toxic effects of the test item were seen at doses of 0.01 µL/plate and higher (without metabolic activation) and at doses of 0.0316 µL/plate and higher (with metabolic activation). In tester strain E. coli WP2 uvrA toxic effects of the test item were noted at doses of 0.0316 µL/plate and higher (without metabolic activation) and at a dose of 0.1 µL/plate (with metabolic activation).
In experiment 2 toxic effects of the test item were noted in tester strains TA 98, TA 100 and TA 1537 at doses of 0.005 µL/plate and higher (without metabolic activation) and at doses of 0.05 µL/plate and higher (with metabolic activation). In tester strain TA 1535 toxic effects of the test item were observed at doses of 0.005 µL/plate and higher (without metabolic activation) and at a dose of 0.05 µL/plate (with metabolic activation). In tester strain E. coli WP2 uvrA toxic effects of the test item were seen at doses of 0.0158 µL/plate and higher (without metabolic activation) and at a dose of 0.1 µL/plate (with metabolic activation).
No biologically relevant increases in revertant colony numbers of any of the five tester strains were observed following treatment with N-Oleyl-1,3-diaminopropane at any concentration level, neither in the presence nor absence of metabolic activation in experiment 1 and 2.
The reference mutagens induced a distinct increase of revertant colonies indicating the validity of the experiments.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 2008-05-14 - 2008-10-08
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- not applicable
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: MEM (minimum essential medium) supplemented with 10% FCS (foetal calf serum)
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver S9-mix (induced with β-naphthoflavone and phenobarbital)
- Test concentrations with justification for top dose:
- Experiment I:
+S9: 0.5, 1.0, 2.0, 4.0, 5.0, 6.5 and 8.0 µg/mL
-S9: 0.2, 0.4, 0.55, 0.7, 0.85, 1.0 and 1.2 µg/mL
Experiment II:
+S9: 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 and 4.5 µg/mL
-S9: 0.05, 0.1, 0.2, 0.4, 0.55, 0.7, 0.85, 1.0 and 1.2 µg/mL - Vehicle / solvent:
- Ethanol
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 400 and 900 µg/mL ethylmethanesulphonate (EMS) and 0.83 µg/mL cyclophosphamide (CPA)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 4 and 20 hours
- Fixation time (start of exposure up to fixation or harvest of cells): 20 hours
SPINDLE INHIBITOR (cytogenetic assays): Colcemid (0.2 µg/mL)
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: duplicates in 2 independent experiments
NUMBER OF CELLS EVALUATED: 200 per concentration
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index
OTHER EXAMINATIONS:
- Determination of polyploidy: yes - Evaluation criteria:
- The chromosomal aberration assay is considered acceptable if it meets the following criteria:
- the number of aberration found in the negative and/or solvent controls falls within the range of historical laboratory control data: 0.0% - 4.5% (+S9) resp. 0.0% - 4.0% (-S9)
- the positive control substances should produce biologically relevant increases in the number of cells with structural chromosome aberrations
Criteria for determinig a positive result:
- a clear and dose-related increase in the number of cells with aberrations,
- a biologically relevant response for at least one of the dose groups, which is higher than the laboratory negative control range (up to 4.5% aberrant cells (+S9) resp. 4.0% aberrant cells (-S9)) - Statistics:
- no data
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Experiment I: at 1.0 µg/mL and higher (-S9) and 4.0 µg/mL and higher (+S9); Experiment II: at 0.4 µg/mL and higher (-S9) and 4.0 µg/mL and higher (+S9)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
The concentration range for the Preliminary Toxicity Test was 0.0078 to 5000 µg/mL without metabolic activation and 1.95 to 5000 µg/mL with metabolic activation. The test item could be dissolved at a concentration of 500 µg/mL in ethanol. After dilution with cell culture medium, precipitation of the test item appeared in a concentration of 15.6 µg/mL and higher.
The selection of the concentrations used in experiment I and II based on data from the solubility and the pre-experiment which were performed according to guidelines. In experiment I (-S9) 1.2 µg/mL and (+S9) 4.0 µg/mL were selected as highest dose groups for the microscopic analysis of chromosomal aberrations. And in experiment II (-S9) 0.4 µg/mL and (+S9) 4.5 µg/mL were selected as highest dose groups for the microscopic analysis of chromosomal aberrations.
COMPARISON WITH HISTORICAL CONTROL DATA: within historical reference range - Remarks on result:
- other: strain/cell type: Chinese hamster lung fibroblasts (V79)
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
In conclusion, it can be stated that during the described in vitro chromosomal aberration test and under the experimental conditions reported, the test item N-Oleyl-1,3-diaminopropane did not induce structural chromosome aberrations in the V79 Chinese hamster cell line. Therefore, the test item N-Oleyl-1,3-diaminopropane is considered to be non-clastogenic. - Executive summary:
The test item N-Oieyl-1‚3-diaminopropane was investigated for a possible potential to induce structural chromosomal aberrations in V79 cells of the Chinese hamster in vitro in the absence and presence of metabolic activation with S9 homogenate.
The selection of the concentrations used in experiment I and II based on data from the solubility test and the pre-experiment which were performed according to the guidelines.
In experiment I without metabolic activation 1.2 µg/mL and with metabolic activation 4.0 µg/mL were selected as highest dose groups for the microscopic analysis of chromosomal aberrations. In experiment II without metabolic activation 0.4 µg/mL and with metabolic activation 4.5 µg/mL were selected as highest dose groups for the microscopic analysis of chromosomal aberrations.
The chromosomes were prepared 20 h after start of treatment with the test item. The treatment intervals were 4 h with and without metabolic activation (experiment I) and 4 h with and 20 h without metabolic activation (experiment II). Two parallel cultures were set up. 100 metaphases per culture were scored for structural chromosomal aberrations.
The following concentrations were evaluated for microscopic analysis:
Experiment I:
with metabolic activation: 1.0, 2.0 and 4.0 µg/mL
without metabolic activation: 0.85, 1.0 and 1.2 µg/mL
Experiment II:
with metabolic activation: 2.5, 4.0 and 4.5 µg/mL
without metabolic activation: 0.1, 0.2 and 0.4 µg/mL
Precipitation:
No precipitation of the test item was noted with and without metabolic activation after the incubation at the concentrations evaluated.
Toxicity:
In experiment I without metabolic activation, a biologically relevant decrease of the relative mitose index (decrease below 70% rel. mitose index) was noted at 1.0 µg/mL and higher (48% at 1.0 µg/mL, 40% at 1.2 µg/mL). The cell density was not decreased. With metabolic activation a biologically relevant decrease of the relative mitose index (decrease below 70% rel. mitose index) was noted at a concentration of 4.0 µg/mL (47% at 4 µg/mL). The cell density was also decreased at this concentration (61%).
In experiment II without metabolic activation, a biologically relevant decrease of the relative mitose index (decrease below 70% rel. mitose index) was noted at 0.4 µg/mL (49%). The cell density was also decreased (65%). With metabolic activation, a biologically relevant decrease of the relative mitose index (decrease below 70% rel. mitose index) was noted at 4.0 µg/mL and higher (46% at 4.0 µg/mL, 30% at 4.5 g/mL). No decrease of the cell density was noted up to the highest dose evaluated.
Clastogenicity:
In the experiment without metabolic activation the aberration rates of the negative control (0.0%) and the solvent control (1.5%) were within the historical control data of the negative control (0.0% - 4.0%). The aberration rates of all dose groups evaluated were within the range of the historical control data. Mean values of 1.0% (0.85 µg/mL), 0.0% (1 and 1.2 µg/mL) aberrant cells were found.
In the experiment with metabolic activation the aberration rates of the negative control (3.5%) and the solvent control (15%) were within the historical control data (0.0% - 4.5%). The aberration rate of all dose groups evaluated were within the range of the historical control data. Mean values of 1.5% (1 µg/mL), 2.0% (2 µg/mL) and 1.0% (4 µg/mL) aberrant cells were found.
In experiment II without metabolic activation the aberration rate of the negative control (1.5%), the solvent control (2.0%) and all dose groups treated with the test item (2,5% (0.1 µg/mL, 0.5% (0.2 µg/mL) and 1.0% (0.4 µg/mL)) were within the historical control data of the testing facility (0.0% - 4.0%). With metabolic activation the aberration rates of the negative control (1.5%), the solvent control (2.5%) and all dose groups treated with the test item (1.5% (2.5 µg/mL), 1.5% (4.0 µg/mL) and 1.0% (4.5 µg/mL)) were within the historical control data of the testing facility (0.0% - 4.5%). The number of aberrant cells found in the dose groups treated with the test item did not show a biologically relevant increase compared to the corresponding negative control, In addition, no dose-response relationship was observed.
Polyploid cells
No biologically relevant increase in the frequencies of polyploid cells was found after treatment with the test item.
EMS (400 and 900 µg/mL) and CPA (0.83 µg/mL) were used as positive controls and induced distinct and biologically relevant increases in cells with structural chromosomal aberration.- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 2008-05-14 - 2010-04-29
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- Hypoxanthine-guanine-phosphoribosyl-transferase (HPRT)
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: MEM (minimal essential medium)
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver S9-mix (indued with β-naphthoflavone and phenobarbital)
- Test concentrations with justification for top dose:
- Experiment I:
-S9: 0.350, 0.425, 0.500, 0.575, 0.650, 0.725, 0.800, 0.875 µg/mL
+S9: 0.05, 0.10, 0.25, 0.5, 1.0, 3.0, 4.0, 5.0 µg/mL
Experiment II:
-S9: 0.1, 0.2, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 µg/mL
+S9: 1.0, 2.0, 3.8, 4.2, 5.0, 5.5, 6.0, 7.0 µg/mL - Vehicle / solvent:
- Ethanol
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 300 µg/mL ethylmethanesulphonate (EMS); 1.0 µg/mL (Experiment I) and 1.5 µg/mL (Experiment II) 7,12-dimethylbenzanthracene(DMBA)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 4, 20 hours
- Expression time (cells in growth medium): 48 to 72 hours after treatment
SELECTION AGENT (mutation assays): thioguanine (TG)
NUMBER OF REPLICATIONS: two independent experiments
DETERMINATION OF CYTOTOXICITY
- Method: cloning efficiency; relative total growth - Evaluation criteria:
- A mutation assay is considered acceptable if it meets the following criteria:
- negative and/or solvent controls fall within the performing laboratories historical control data range: 1 - 39 mutants/10E6 cells
- the absolute cloning efficiency: ([number of positive cultures x 100] / total number of seeded cultures) of the negative and/or solvent controls is > 50%
- the spontaneous mutant frequency in the negative and/or solvent controls is in the range of historical control data
- the positive controls (EMS and DMBA) induce significant increases (at least 3-fold increase of mutant frequencies related to the comparable negative control values and higher than the historical range of negative controls) in the mutant frequencies.
Atest is considered negative if there is no biological relevant increase in the number of mutants. There are several criteria for determining a positive result:
- a reproducible 3-times higher mutation frequency than the solvent control for at least one of the concentrations
- a concentration related increase of the mutation frequency; such an evaluation may be considered also in the case that a 3-fold increase of the mutant frequency is not observed. - Statistics:
- No data
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Experiment I: at 0.875 µg/mL (-S9) and at 5.0 µg/mL (+S9); Experiment II: at 0.9 µg/mL (-S9) and at 7.0 µg/mL (+S9)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
The toxicity of the test item was based on data from pre-experiment. Eight concentrations were tested: 0.0625 - 4.0 µg/mL (-S9) and 0.125 - 3.0 µg/mL (+S9).
In experiment I 0.875 µg/mL (-S9) and 5 µg/mL (+S9) were selected as the highest concentrations. In experiment II 0.9 µg/mL (-S9) and 7 µg/mL [+S9) were selected as the highest concentrations. Experiment II without metabolic activation was performed as a 20 h long-term exposure assay.
COMPARISON WITH HISTORICAL CONTROL DATA:
All values of the negative controls and test item concentrations found were within the historical control data - Remarks on result:
- other: strain/cell type: Chinese hamster lung fibroblasts (V79)
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
In conclusion, in the described in vitro cell gene mutagenicity test under the experimental conditions reported, the test item N-Oleyl-1,3-diaminopropane is considered to be non-mutagenic in the HPRT locus using V79 cells of the Chinese hamster. - Executive summary:
The test item N-Oleyl-1,3-diaminopropane was assessed for its potential to induce gene mutations at the HPRT locus using V79 cells of the Chinese hamster according to the OECD guideline 476.
The main experiments were carried out without and with metabolic activation. The experiments with metabolic activation were performed by including liver microsomes and NADP for efficient detection of a wide variety of carcinogens requiring metabolic activation.
The selection of the concentrations used in the main experiments was based on data from the pre-experiments according to the OECD guideline 476.
In experiment I 0.875 µg/mL (without metabolic activation) and 5.0 µg/mL (with metabolic activation) were selected as the highest concentrations. In experiment II 0.9 µg/mL (without metabolic activation) and 7.0 µg/mL (with metabolic activation) were selected as the highest concentrations. Experiment II without metabolic activation was performed as a 20 h long-term exposure assay.
The pH-value detected with the test item was within the physiological range. The test item was investigated at the following concentrations:
Experiment I
without metabolic activation:
0.350, 0.425, 0.500, 0.575, 0.650, 0.725, 0.800 and 0.875 µg/mL
and with metabolic activation:
0.05, 0.10, 0.25,0.5,1.0, 3.0, 4.0 and 5.0 µg/mL
Experiment II
without metabolic activation:
0.1, 0.2, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9 µg/mL
and with metabolic activation:
1.0, 2.0, 3.8, 4.2, 5.0, 5.5, 6.0 and 7.0 µg/mL
No precipitation oft he test item was noted in experiment I and experiment II.
Toxicity:
A biologically relevant growth inhibition (reduction of relative growth below 70%) was observed after the treatment with the test item in experiment I and II with and without metabolic activation.
In experiment I without metabolic activation the relative growth was 13.6% for the highest concentration (0.875 µg/mL) evaluated. The highest biologically relevant concentration evaluated with metabolic activation was 5.0 µg/mL with a relative growth of 10.1%.
In experiment II without metabolic activation the relative growth was 12.6% for the highest concentration (0.9 µg/mL) evaluated. The highest biologically relevant concentration evaluated with metabolic activation was 7.0 µg/mL with a relative growth of 16 .5%.Mutagenicity:
In experiment I without metabolic activation mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 1 - 39 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the negative controls.
Mutation frequencies with the negative control were found to be 11.48 and 14.58 mutants/106 cells, 14.08 and 6.48 mutants/106 cells for the solvent control and in the range of 3.96 to 25.42 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the solvent control values) of 2.47 was found at a concentration of 0.425 µg/mL with a relative growth of 98.6%.
With metabolic activation all mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 2 - 28 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the solvent controls.
Mutation frequencies of the negative control were found to be 10.80 and 28.34 mutants/106 cells, 11.96 and 7.51 mutants/106 cells for the solvent control and in the range of 7.85 to 22.85 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the solvent control values) of 2.35 was found at a concentration of 4.0 µg/mL with a relative growth of 47.2%.
In experiment II without metabolic activation all mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 1 - 39 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the solvent controls.
Mutation frequencies with the negative control were found to be 5.47 and 11.67 mutants/106 cells, 5.76 and 10.65 mutants/106cells for the solvent control and in the range of 2.98 to 13.70 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the solvent controls values) of 1.67 was found at a concentration of 0.5 µg/mL with a relative growth of 62.0%.
In experiment II with metabolic activation most mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 2 - 28 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the solvent controls.
Mutation frequencies of the negative control were found to be 16.02 and 8.77 mutants/106 cells, 16.36 and 1.20 mutants/106 cells for the solvent control and in the range of 2.75 to 9.34 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the solvent control values) of 1.06 was found at a concentration of 1.0 µg/mL with a relative growth of 95%.
DMBA (1.0 and 1.5 µg/mL) and (300 µg/mL) were used as positive controls and showed distinct and biologically relevant effects in mutation frequency.
Referenceopen allclose all
Table 1: Ames Test Results - Experiment 1
With or without S9-Mix |
Test substance concentration (dose/plate) |
Mean number of revertant colonies per plate (triplicates) |
||||
Base-pair substitution type |
Frameshift type |
|||||
TA 100 |
TA 1535 |
E. coli WP2 uvrA |
TA 98 |
TA 1537 |
||
- |
A. dest. |
95 |
20 |
53 |
28 |
6 |
- |
Vehicle control (EtOH) |
102 |
23 |
46 |
24 |
6 |
- |
0.000100µL |
96 |
17 |
42 |
29 |
9 |
- |
0.000316 µL |
67 |
16 |
45 |
23 |
10 |
- |
0.00100 µL |
94 |
26 |
46 |
26 |
11 |
- |
0.00316 µL |
67 |
24 |
46 |
24 |
7 |
- |
0.0100 µL |
41 |
13 |
53 |
15 |
4 |
- |
0.0316 µL |
0 |
0 |
0 |
0 |
0 |
- |
0.1 µL |
0 |
0 |
0 |
0 |
0 |
Positive controls - S9 |
Name |
NaN3 |
NaN3 |
MMS |
4-NOPD |
4-NOPD |
Concentrations (μg/plate) |
10 µg |
10 µg |
1 µL |
10 µg |
40 µg |
|
Number of colonies/plate |
1257 |
1145 |
407 |
395 |
99 |
|
|
TA 100 |
TA 1535 |
E. coli WP2 uvrA |
TA 98 |
TA 1537 |
|
+ |
A. dest. |
99 |
19 |
56 |
33 |
10 |
+ |
Vehicle control (EtOH) |
97 |
23 |
57 |
38 |
11 |
+ |
0.000100µL |
108 |
29 |
56 |
40 |
9 |
+ |
0.000316 µL |
103 |
23 |
46 |
36 |
7 |
+ |
0.00100 µL |
112 |
25 |
63 |
44 |
8 |
+ |
0.00316 µL |
114 |
26 |
62 |
43 |
11 |
+ |
0.0100 µL |
129 |
25 |
69 |
41 |
13 |
+ |
0.0316 µL |
62 |
13 |
66 |
21 |
6 |
+ |
0.1 µL |
0 |
0 |
15 |
0 |
0 |
Positive controls + S9 |
Name |
2-AA |
2-AA |
2-AA |
2-AA |
2-AA |
Concentrations (μg/plate) |
2.5 µg |
2.5 µg |
10 µg |
2.5 µg |
2.5 µg |
|
Number of colonies/plate |
2209 |
243 |
204 |
3114 |
211 |
Table 2: Ames Test Results - Experiment 2
With or without S9-Mix |
Test substance concentration (dose/plate) |
Mean number of revertant colonies per plate (triplicates) |
||||
Base-pair substitution type |
Frameshift type |
|||||
TA 100 |
TA 1535 |
E. coli WP2 uvrA |
TA 98 |
TA 1537 |
||
- |
A. dest. |
134 |
26 |
54 |
21 |
7 |
- |
Vehicle control (EtOH) |
134 |
31 |
51 |
30 |
7 |
- |
0.000050µL |
- |
32 |
- |
- |
- |
- |
0.000158µL |
126 |
24 |
56 |
29 |
9 |
- |
0.0005 µL |
124 |
28 |
53 |
23 |
7 |
- |
0.00158 µL |
117 |
19 |
50 |
22 |
12 |
- |
0.005 µL |
75 |
15 |
50 |
26 |
8 |
- |
0.0158 µL |
13 |
0 |
35 |
3 |
0 |
- |
0.05 µL |
0 |
0 |
0 |
0 |
0 |
- |
0.1 µL |
0 |
- |
0 |
0 |
0 |
Positive controls - S9 |
Name |
NaN3 |
NaN3 |
MMS |
4-NOPD |
4-NOPD |
Concentrations (μg/plate) |
10 µg |
10 µg |
1 µL |
10 µg |
40 µg |
|
Number of colonies/plate |
1519 |
1537 |
447 |
528 |
112 |
|
|
TA 100 |
TA 1535 |
E. coli WP2 uvrA |
TA 98 |
TA 1537 |
|
+ |
A. dest. |
105 |
21 |
56 |
39 |
13 |
+ |
Vehicle control (EtOH) |
81 |
22 |
53 |
37 |
9 |
+ |
0.000050µL |
- |
28 |
- |
- |
- |
+ |
0.000158µL |
108 |
29 |
67 |
37 |
11 |
+ |
0.0005 µL |
89 |
25 |
64 |
42 |
6 |
+ |
0.00158 µL |
97 |
25 |
61 |
45 |
8 |
+ |
0.005 µL |
103 |
17 |
51 |
40 |
8 |
+ |
0.0158 µL |
112 |
22 |
50 |
41 |
17 |
+ |
0.05 µL |
24 |
0 |
66 |
0 |
0 |
+ |
0.1 µL |
0 |
- |
2 |
0 |
0 |
Positive controls + S9 |
Name |
2-AA |
2-AA |
2-AA |
2-AA |
2-AA |
Concentrations (μg/plate) |
2.5 µg |
2.5 µg |
10 µg |
2.5 µg |
2.5 µg |
|
Number of colonies/plate |
1611 |
181 |
231 |
2440 |
328 |
NaN3= Sodium azide
MMS = Methyl methane sulfonate
4-NOPD = 4-Nitro-o-phenylene-diamine
2-AA = 2-Aminoanthracene
Summary of aberration rates in experiment I
Dose Group |
Concentration [µg/mL] |
Treatment Time |
Fixation Interval |
Mean % aberrant cells |
|
incl. Gaps |
excl. Gaps |
||||
without metabolic activation |
|||||
C |
0 |
4 h |
20 h |
2.0 |
0.0 |
S |
0 |
4 h |
20 h |
4.5 |
1.5 |
5 |
0.85 |
4 h |
20 h |
3.5 |
1.0 |
6 |
1.0 |
4 h |
20 h |
0.5 |
0.0 |
7 |
1.2 |
4 h |
20 h |
0.5 |
0.0 |
EMS |
900 |
4 h |
20 h |
11.5 |
8.5 |
with metabolic activation |
|||||
C |
0 |
4 h |
20 h |
5.0 |
3.5 |
S |
0 |
4 h |
20 h |
2.0 |
1.5 |
2 |
1.0 |
4 h |
20 h |
4.5 |
1.5 |
3 |
2.0 |
4 h |
20 h |
4.5 |
2.0 |
4 |
4.0 |
4 h |
20 h |
3.5 |
1.0 |
CPA |
0.83 |
4 h |
20 h |
10.5 |
9.0 |
Summary of aberration rates in experiment II
Dose Group |
Concentration [µg/mL] |
Treatment Time |
Fixation Interval |
Mean % aberrant cells |
|
incl. Gaps |
excl. Gaps |
||||
without metabolic activation |
|||||
C |
0 |
20 h |
20 h |
3.0 |
1.5 |
S |
0 |
20 h |
20 h |
3.5 |
2.0 |
5 |
0.1 |
20 h |
20 h |
4.0 |
2.5 |
6 |
0.2 |
20 h |
20 h |
2.0 |
0.5 |
7 |
0.4 |
20 h |
20 h |
3.0 |
1.0 |
EMS |
400 |
20 h |
20 h |
12.0 |
8.0 |
with metabolic activation |
|||||
C |
0 |
4 h |
20 h |
4.0 |
1.5 |
S |
0 |
4 h |
20 h |
4.5 |
2.5 |
2 |
2.5 |
4 h |
20 h |
3.5 |
1.5 |
3 |
4.0 |
4 h |
20 h |
3.0 |
1.5 |
4 |
4.5 |
4 h |
20 h |
2.5 |
1.0 |
CPA |
0.83 |
4 h |
20 h |
11.5 |
8.5 |
200 cells evaluated for each concentration
C: Negative control (culture medium)
S: Solvent control (Ethanol)
EMS: Positive control (-S9: ethylmethansulfonate)
CPA: Positive control (+S9: cyclophosphamide)
Table 1: Experiment I - without metabolic activation
Dose Group |
Concentration [µg/mL] |
Relative Growth [%] |
Factor* (survived cells / seeded cells) |
Mutant colonies per 10E6 cells |
Mutation factor |
NC1 |
0 0 |
125.1 |
0.78 |
11.48 |
|
NC2 |
133.3 |
0.82 |
14.58 |
||
S1 |
0 0 |
100.0 100.0 |
0.78 |
14.08 |
|
S2 |
0.69 |
6.48 |
|||
5 |
0.350 |
104.1 |
0.73 |
18.49 |
1.80 |
6 |
0.425 |
98.6 |
0.71 |
25.42 |
2.47 |
7 |
0.500 |
90.9 |
0.81 |
8.07 |
0.79 |
8 |
0.575 |
80.5 |
0.81 |
24.66 |
2.40 |
9 |
0.650 |
53.5 |
0.75 |
22.09 |
2.15 |
10 |
0.725 |
51.9 |
0.74 |
14.29 |
1.39 |
11 |
0.800 |
33.2 |
0.74 |
24.19 |
2.35 |
12 |
0.875 |
13.6 |
0.63 |
3.96 |
0.39 |
EMS |
300 |
105.9 |
0.82 |
150.37 |
14.62 |
Table 2: Experiment I - with metabolic activation
Dose Group |
Concentration [µg/mL] |
Relative Growth [%] |
Factor* (survived cells / seeded cells) |
Mutant colonies per 10E6 cells |
Mutation factor |
NC1 |
0 0 |
103.0 |
0.97 |
10.80 |
|
NC2 |
114.6 |
0.69 |
28.34 |
||
S1 |
0 0 |
100.0 100.0 |
0.84 |
11.96 |
|
S2 |
0.87 |
7.51 |
|||
1 |
0.05 |
97.8 |
0.83 |
21.79 |
2.24 |
2 |
0.10 |
82.0 |
0.72 |
13.81 |
1.42 |
3 |
0.25 |
83.9 |
0.84 |
19.69 |
2.02 |
4 |
0.5 |
79.8 |
0.83 |
7.85 |
0.81 |
5 |
1.0 |
81.3 |
0.71 |
21.86 |
2.25 |
6 |
3.0 |
68.5 |
0.73 |
17.08 |
1.75 |
7 |
4.0 |
47.2 |
0.72 |
22.85 |
2.35 |
8 |
5.0 |
10.1 |
0.57 |
14.13 |
1.45 |
DMBA |
1.0 |
67.0 |
0.68 |
147.19 |
15.12 |
Table 3: Experiment II - without metabolic activation
Dose Group |
Concentration [µg/mL] |
Relative Growth [%] |
Factor* (survived cells / seeded cells) |
Mutant colonies per 10E6 cells |
Mutation factor |
NC1 |
0 0 |
115.5 |
0.87 |
5.74 |
|
NC2 |
105.7 |
0.90 |
11.67 |
||
S1 |
0 0 |
100.0 100.0 |
0.87 |
5.76 |
|
S2 |
0.75 |
10.65 |
|||
5 |
0.1 |
80.6 |
0.56 |
8.06 |
0.98 |
6 |
0.2 |
80.6 |
0.56 |
11.71 |
1.43 |
7 |
0.4 |
67.9 |
0.76 |
1060 |
1.29 |
8 |
0.5 |
62.0 |
0.51 |
13.70 |
1.67 |
9 |
0.6 |
38.2 |
0.94 |
8.55 |
1.04 |
10 |
0.7 |
27.7 |
0.84 |
12.54 |
1.53 |
11 |
0.8 |
26.7 |
0.67 |
2.98 |
0.36 |
12 |
0.9 |
12.6 |
0.99 |
9.06 |
1.10 |
EMS |
300 |
49.3 |
0.57 |
184.12 |
22.44 |
Table 4: Experiment II - with metabolic activation
Dose Group |
Concentration [µg/mL] |
Relative Growth [%] |
Factor* (survived cells / seeded cells) |
Mutant colonies per 10E6 cells |
Mutation factor |
NC1 |
0 0 |
118.5 |
0.75 |
16.02 |
|
NC2 |
96.0 |
0.68 |
8.77 |
||
S1 |
0 0 |
100.0 100.0 |
0.86 |
16.36 |
|
S2 |
0.84 |
1.20 |
|||
2 |
1.0 |
95.0 |
0.70 |
9.34 |
1.06 |
3 |
2.0 |
95.0 |
0.68 |
4.39 |
0.50 |
5 |
3.8 |
85.0 |
0.72 |
6.23 |
0.71 |
6 |
4.2 |
80.0 |
0.74 |
6.11 |
0.70 |
7 |
5.0 |
70.0 |
0.78 |
3.19 |
0.36 |
8 |
5.5 |
65.0 |
0.55 |
2.75 |
0.31 |
9 |
6.0 |
40.0 |
0.75 |
8.70 |
0.99 |
10 |
7.0 |
16.5 |
0.79 |
5.06 |
0.58 |
DMBA |
1.5 |
80.0 |
0.87 |
116.09 |
13.23 |
NC: negative control / medium control
SC: solvent control (ethanol)
*: cloning efficiency x cells seeded
EMS: Ethylmethansulfonate
DMBA: 7,12 -Dimethylbenz(a)anthracene
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
Lack of genotoxic properties of alkyl-diamines was further confirmed in anin vivomicronucleus study with Coco-diamine, conducted according to OECD 474 guideline and under GLP.
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 1991
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study performed under GLP and according to standard protocol.
- Qualifier:
- according to guideline
- Guideline:
- other: 40 CFR Part 158 US-EPA-FIFRA, Section 158.340, Guideline 84-3
- Principles of method if other than guideline:
- This method is similar to OECD474. The humidity was out of the recommended range of 50-60%. It was8-53% this deviation is not thought to have influenced the outcome of the study.
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- Swiss Webster
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc.
- Age at study initiation: Approximately 6 weeks (born on approximately November 21, 1990)
- Weight at study initiation: one or two mice from each cage were selected randomly to be weighed. The weights of 17 male mice ranged from 21.8 to 26.7 g and those of 15 female mice from 18.7 to 22.7 g at the time of receipt.
- Assigned to test groups randomly: yes
- Fasting period before study: no data
- Housing: Mice were housed no more than 10 to a cage dufing quarantine, 3 to a cage for the range-finding assay, and 5 to a cage during the definitive assay. Polycarbmate cages with hardwood-chip bedding were used throughout the study.
- Diet (e.g. ad libitum): ad libitum; Purina Certified Rodent Chow #5002 ad libitum. Purina Mills, Inc., St. muis, MO. Lot no. NOV05901C.
- Water (e.g. ad libitum): Deionized tap water ad libitum via an automatic watering system.
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-25.5
- Humidity (%): 8-53
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12 hours light/l2 hours dark
IN-LIFE DATES: From: 1990-11-10 To: - - Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: corn oil
- Justification for choice of solvent/vehicle: standard; well-known, non-toxic
- Concentration of test material in vehicle: no data
- Amount of vehicle (if gavage or dermal): 10ml/kg
- Lot/batch no. (if required): M05X1
- Purity: no data - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test chemical was mixed well in corn oil immediately before dosing.
Assays to verify concentration, stability, and homogeneity of the test substance in the carrier vehicle were not performed. - Duration of treatment / exposure:
- Animals w ill be dosed once each day on two consecutive days.
- Frequency of treatment:
- Animals w ill be dosed once each day on two consecutive days.
- Post exposure period:
- Animals are sacrificed 24 or 48 hours after the second dose.
- Remarks:
- Doses / Concentrations:
range finding: 0, 150, 300, 600, 1200, 2500, or 5000 mg/kg day
Basis:
other: administered by gavage - Remarks:
- Doses / Concentrations:
main study:0, 31.3, 62.5, or 125 mg/kg/day
Basis:
other: administered by gavage - No. of animals per sex per dose:
- range finding: 3
main study: 10 - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- benzene
- Justification for choice of positive control(s): known clastogen
- Route of administration: oral gavage in corn oil
- Doses / concentrations: 500 mg/kg day
administered to male mice only - Tissues and cell types examined:
- Peripheral blood smears were analyzed for the polychromatic erythrocyte (PCE) to red blood cell (RBC) ratio in the range-finding assay. Bone marrow smears were analyzed for micronucleus in both the range-finding and definitive assays.
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: range finding study
TREATMENT AND SAMPLING TIMES: no additional data
DETAILS OF SLIDE PREPARATION:
Peripheral blood smears were analyzed for the polychromatic erythrocyte (PCE) to red blood cell (RBC) ratio in the range-finding assay. Blood samples were obtained by pricking the ventral tail vessel with a 25-gauge needle and drawing 2-3 µl of blood into a capillary lube. The sample was transferred to three clean, prelabeled microscope slides per mouse, spread, air-dried, fixed in absolute methanol for 5 minutes, and stored until staining. Two of the three prepared slides were coded, Both coded slides from each test animal were visually examined, and the slide with the most uniform
preparation of smear was stained with acridine orange. Unstained slides were filed for future use should extras be needed.
Bone marrow smears were analyzed in both the range-finding and definitive assays. The right femur from each mouse was removed and
flushed gently with 0.2 ml of fetal bovine serum (FBS) into 0.5 ml of FBS in a 2-ml conical polycarbonate tube. Cells were concentrated by
centrifugation and then resuspended in an equal volume of supernate. The sample was transferred to three clean, prelabeled microscope
slides per mouse, spread, air-dried, fixed in absolute methanol for 5 minutes, and stored until staining. Two of the three prepared slides
were coded. Both coded slides from each test animal were visually examined, and the slide with the most uniform preparation of smear was
stained with acridine orange. Unstained slides were filed for future use should extras be needed.
METHOD OF ANALYSIS:
Peripheral blood smears and bone marrow smears were evaluated using epifluorescence microscopy.
Other: Criteria for a Valid Assay
The data from this assay were considered acceptable if
(1) the frequency of micronucleated cells in the vehicle control group was within the normal historical range,
(2) administration of the positive
control substance resulted in a statistically significant elevation of micronucleated cells
(3) there were at least three surviving animals of each sex with a percentage of RNA-positive erythrocytes greater than or equal to 15% of the control value. - Evaluation criteria:
- In the range-finding assay, peripheral blood smears and bone marrow smears were analyzed for the number of RNA-positive polychromatic erythrocytes in at least 500 and 200 erythrocytes, respectively, per animal, In the definitive assay, two parameters were determined in the bone marrow smears: (1) the number of micronucleated RNA-positive erythrocytes in at least 1000 RNA-positive erythrocytes per animal, which provides an index of - chromosomal damage; and (2) the number of RNA-positive erythrocytes in at least 200 erythrocytes per animal, which provides an index of cytotoxicity to the nucleated erythrocyte precursors.
The criteria used for MN are those described by Schmid (1976), with the additional requirement that the MN exhibit fluorescence characteristic of the stain used (i.e., bright yellow in the case of acridine orange). The ratio of RNA-containing erythrocytes to mature erythrocytes (RBC) was based on the number of RNA-positive cells in approximately 200 erythrocytes. Data from a given slide were directly captured by an IBM PC computer data file during scoring. After analysis, the slides were decoded and data summarized using a decoding program on an IBM PC. - Statistics:
- Data were analyzed according to sex. The ratio of micronucleated RNA-containing erythrocytes (i. e. , micronucleated PCE) to RNA-positive
erythrocytes and the RNA-positive erythrocytes as a percentage of total erythrocytes were calculated for each animal. The statistical
significance of differences in the percentage of RNA-positive erythrocytes among groups was evaluated using the Kruskall-Wallace
analysis of variance on ranks (calculated using the SAS software package on an IBM PC). In experiments where the frequencies of micronucleated cells are determined by scoring 1000 cells per animal, data are not expected to be distributed normally. Such data were analyzed using the Cochran-
Armitage test (using an SRI-developed software package on an IBM PC) for trends in binomial proportions (to determine a significant doseresponse
relationship) and the normal test for equality of binomial proportions (to determine if values for individual dose groups were'
statistically different from those for controls) (Kastenbaum and Bowman, 1970; an SRI-developed software package on an IBM PC was
used). These tests and the rationale for each are discussed in the ASTM Standard Guide for Conduct of Micronucleus Assays in mammalian
Bone Marrow Erythrocytes (ASTM Committee, 1988) and in Margolin et al; (1983). - Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- Salient clinical signs included rough fur and loose stools in all Duomeen C dosage groups. One test-substance-related death was observed in the 62.5 mg/kg/day dosage group. Cytotoxicity, as indicated by a slight decrease in the PCE/RBC ratio was observed
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- see attached tables
- Conclusions:
- Interpretation of results (migrated information): negative
It was concluded that Duomeen C at dosages up to and including the MTD of 125 mg/kg/day did not induce increased incidences of
micronuclei in the bone marrow erythrocytes of male and female Swiss- Webster mice. Therefore, Duomeen C was considered to be nongenotoxic
under these test conditions. - Executive summary:
The genotoxic potential of orally administered N-C12-18-alkyltrimethylenediamine (Coco-diamine) to induce micronucleus formation in bone marrow erythrocytes was determined in Swiss-Webster mice.
The study was conducted according to OECD 474 guideline and under GLP.
In the range-finding assay, three mice per sex received orally administered Coco-diamine in corn oil at dosage levels of 150, 300, 600, 1200, 2500, or 5000 mg/kg body weight/day (mg/kg/day) to determine a maximum tolerated dosage (MTD) that would be used in setting dosages for the definitive study. A control group of three male and three female mice received corn oil only. All mice were observed and dosed for two consecutive days. Mice surviving the dosing regimen were euthanized 48 hours after the administration of the last dose and evaluated for specific signs of cytotoxicity reflected in hematopoietic indices.
All mice receiving dosages of 300 mg/kg/day or greater died on study, while in the 150 mg/kg/day dosage group only one male mouse died. Adverse clinical observations reported for the 150 mg/kg/day dosage group included decreased body weight in female mice. A set number of erythrocytes in both bone marrow and peripheral red blood cell (RBC) pools from mice surviving to euthanasia were examined and the number of RNA-positive (polychromatic) erythrocytes was counted to determine cellularity and the frequency of PCEs among erythrocytes. Suppression of PCE/RBC ratio to approximately 65% of that of the corn oil control group was observed in both pools from mice receiving doses of 150 mg/kg/day. From this suppression and the minimal mortality observed at 150 mg/kg/day, an MTD of approximately 125 mg/kg/day was determined for Coco-diamine.
In the definitive assay, at least 10 mice per sex per dosage group were orally administered Coco-diamine in corn oil dosage levels of 31.3, 62.5, or 125 mg/kg/day for two consecutive days. Five mice per sex per dosage group were euthanized 24 hours after the final dose and the same number 48 hours after the final dose; all were evaluated for cytotoxicity and micronucleus formation in bone marrow erythrocytes. A corn oil vehicle control group (10 mice per sex) and a benzene positive control group (10 male mice only) were treated similarly and evaluated concurrently with test groups. Salient clinical signs included rough fur and loose stools in all Coco-diamine dosage groups. One test-substance-related death was observed in the 62.5 mg/kg/day dosage group. Cytotoxicity, as indicated by a slight decrease in the PCE/RBC ratio was observed in both sexes in the top two dosage groups of Coco-diamine. However, all Coco-diamine-treated groups, when compared to that of the corn oil control group, had average micronucleus counts approximately equal to that of the control groups. Background micronucleus incidences in bone marrow' erythrocytes of male and female mice treated with corn oil alone averaged 0.18% and 0.22%, respectively. The benzene positive control induced micronucleus rates at least 5-fold greater than that of the background.
In summary, Coco-diamine at dosages up to and including the MTD of 125 mg/kg/day did not induce increased incidences of micronuclei in the bone marrow erythrocytes of Swiss-Webster mice. Therefore, Coco-diamine was considered to be non-genotoxic under these test conditions.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Mode of Action Analysis / Human Relevance Framework
Based on structure and mechanism of cytotoxicity, genototoxicity by alkyl-diamines is not expected. In physiological circumstances, the diamines have a cationic surfactant structure which leads to high adsorptive properties to negatively charged surfaces as cellular membranes. The apolar tails easily dissolve in the membranes, whereas the polar head causes disruption and leakage of the membranes leading to cell damage or lysis of the cell content. As a consequence, the whole molecule will not easily pass membrane structures. Noteworthy in this respect is that recent research shows that the log distribution coefficient for cationic surfactants between water and phospholipid are possibly several orders of magnitude higher than between water and oil.
Cytotoxicity through disruption of cell membrane will occur rather than absorption over the cell membrane into the cell and transfer to the nucleus to interact with DNA.
Additional information
Applicability cross-reading:
There is no study available on Diamine C16-18, C18-unsaturated (“tallow-diamine”) itself.
Use is additionally made of cross-reading, using studies from (Z)-N-9-octadecenyl-1,3-diaminopropane, CAS 7173-62-8), further referred to as Oleyl-diamine.
Tallow-diamine and Oleyl-diamine are very similar, sharing the same alkyl-diamine structure, resulting to the same functional groups with similar properties leading to common biological activity, and common metabolic degradation. There is only a slight difference in the variation in alkyl-chain lengths, and therefore results obtained with the one product are also considered to be fully relevant for the other. The higher level of unsaturation in oleyl-alkyl chains can be considered a worst case representation, although the higher average chain length could be regarded as a disadvantage in that respect. Further support for read-across can be obtained from the document "Category polyamines - 20170518.pdf" added to IUCLID Ch. 13.
Available data:
N-Oleyl-1,3-diaminopropane, CAS 7173-62-8,was tested for genetic toxicity in three in vitro tests. In a bacterial reverse mutation assay the substance was not mutagenic with or without S9 mix. It was also tested for mammalian cell gene mutations at the HPRT locus using V79 cells of the Chinese hamster and was not mutagenic. In addition, the substance was tested in a chromosomal aberration test in human lymphocytes and was found to be not clastogenic. All tests were to current OECD/EU protocols carried out to GLP and with a clearly defined and described test substance. Based on these results it can be concluded that N-Oleyl-1,3-diaminopropane is not to be expected to be a genotoxic hazard to human health.
Based on structure and mechanism of cytotoxicity, genototoxicity by alkyl-diamines is not expected. In physiological circumstances, the diamines have a cationic surfactant structure which leads to high adsorptive properties to negatively charged surfaces as cellular membranes. The apolar tails easily dissolve in the membranes, whereas the polar head causes disruption and leakage of the membranes leading to cell damage or lysis of the cell content. As a consequence, the whole molecule will not easily pass membrane structures. Cytotoxicity through disruption of cell membrane will occur rather than absorption over the cell membrane into the cell and transfer to the nucleus to interact with DNA.
Further information supporting the lack of genotoxic properties comes from the profiling of alkyl-diamines with varying chain length from C10 to C18, and including C18-unsaturated (Oleyl-diamine). (QSAR Toolbox v.4.1). There are no alerts are found for DNA interaction, protein interactions and no DNA alerts for Ames, MN and CA (OASIS v1.1).
Selecting in QSAR Toolbox all primary amines (from OECD HPV profile - total 1750 selected), and removing all compounds that are not discrete chemical and having other atoms besides carbon and nitrogen results to 306 relevant primary amines. From these there are 764 genotoxicity data points reported belonging to 68 of these subcategorized substances. Evaluation of all mutagenicity related data (608 data points of the 764), there was only one positive mutagenic result present, belonging to naphthylethylenediamine. This indicates a lack of mutagenic properties for the primary amines category of chemicals, to which the diamines also belong.
Information from QSARs on alkyl-diamine structures also showed no indication for mutagenicity:
- VEGA (Mutagenicity models CAESAR version 2.1.10; SarPy model, version 1.0.5-BETA): Predicts non-mutagenic, both with high reliability, but with the indication that compound could be out of the Applicability Domain of the model.
- DEREK (Derek Nexus: 3.0.1, Nexus: 1.5.0): Nothing to report on mutagenicity
- TOPKAT (Accelrys ADMET Toxicity Prediction (Extensible)) predicts non-mutagen, with high validity for oleyl-diamine, C18-diamine and C10-diamine (probability for mutagenicy of 0, 0.007 and 0.047 resp.).
- QSAR Toolbox v.3.0 contains series of QSAR for nodes under Human Health Hazards Genetic Toxicity that are all from Danish EPA DB. All eightIn vitroestimations and threein vivoestimations predicted negative genotoxicity for alkyl-diamine structures (in vitro:Ames test (Salmonella); UDS; DNA react. (Ashby fragments); Chrom. abber. (CHO); Mouse, COMET assay; HGPRT; Syrian hamster embryo cells; SCE;In vivo:Rodent, Dominant lethal; Drosophila sex-linked recessive lethal; Mouse micronucleus.).
Also the combined dataset of performed studies evaluating the genotoxicity hazards of alkyl-diamines substances indicate that alkyl-diamines do not have genotoxic properties. All of the available studies showed negative responses.
Available data on alkyl-diamines:
Test System or Species, Strain, Age, Number, and Sex of Animals |
Biological Endpoint |
S9 |
Chemical Form and Purity, vehicle |
Dose |
Results/Comments |
Reference |
Prokaryotic Systems |
||||||
OECD 471, GLP S. typhimurium strainsTA 1535, TA 1537, TA 98 and TA 100 |
Increase in revertants due to mutations |
+/- |
Duomeen C Coco-diamine, 98.7% in DMSO |
+S9: 0.33, 1.0, 3.3, 10.0, 33.3 µg/plate -S9: 3.3, 10.0, 33.3, 100 µg/plate |
No mutagenic effects observed. Highest dose 1000 µg/plate was based on toxicity pre-test, Highest dose is selected to show slight toxicity. |
Proprietary RCC Notox, 1990 031444 |
OECD 471, GLP S. typhimurium strainsTA98, TA100, TA1535, TA1537;Escherichia coliWP2 uvrA |
Increase in revertants due to mutations |
+/- |
Genamin LAP 100D C12-diamine purity 100% in ethanol; |
(0.16), 0.5, 1.6, 5, 16, 50, 160 µg/plate with and without S9 |
Precipitation at 5000 µg/plate No mutagenic effects observed under the test conditions. Toxic concentration observed for bacteria from 160 μg/ with and from 50 µg/plate without activation. |
Proprietary Aventis, 2003 PT03-0028 |
OECD 471, GLP S. typhimurium strainsTA98, TA100, TA1535, TA1537;Escherichia coliWP2 uvrA |
Increase in revertants due to mutations |
+/- |
Duomeen HT HT-diamine Purity np In ethanol |
Exp.1: 0.316, 0.1, 3.16, 10.0, 31.6, 100, 316, 1000 and 2500 µL/plate Exp.2: 0.158, 0.50, 1.58, 5.0, 15.8, 50 , 158, 500 and 1580 µL/plate |
Precipitation from 31.6 µg/plate without S9 and from 500 µg/plate with S9. No mutagenic effects observed under the test conditions. Toxic concentration observed for bacteria from 10 μg/plate without and from 100 µg/plate with activation. |
Proprietary BSL, 2008 081561 |
OECD 471, GLP S. typhimurium strainsTA 1535, TA 1537, TA 1538, TA 98 and TA 100 |
Increase in revertants due to mutations |
+/- |
Dinoram SH HT-diamine 90% In ethanol |
1, 5, 10, 25 and 50 mg /plate.
|
No mutagenic effects observed under the test conditions. Toxicity was observed from 50 µg/plate and higher |
Proprietary CIT, 1986 2097 MMO |
OECD 471, GLP S. typhimurium strainsTA98, TA100, TA1535, TA1537;Escherichia coliWP2 uvrA |
Increase in revertants due to mutations |
+/- |
Duomeen OV Oleyl-diamine 92.3% In Ethanol |
Exp.1: 0.00010, 0.000316, 0.00100, 0.00316, 0.0100, 0.0316 and 0.1 µL/plate Exp.2: 0.000050, 0.000158, 0.00050, 0.00158, 0.0050, 0.0158, 0.05 and 0.1 µL/plate |
No precipitation of the test item was observed. No mutagenic effects observed under the test conditions. Toxic concentration observed for bacteria from 0.00316 µL/plate without and from 0.0316 µL/plate with activation. |
Proprietary BSL, 2008 081576 |
Mammalian SystemsIn Vitro |
||||||
OECD 473, GLP CHL (V79) |
Chromosomal aberration |
+/- |
Genamin LAP 100D C12-diamine purity 100% in ethanol; |
+S9: 0.16, 0.32, 0.64, 1.28 µg/ml -S9 3h: 0.16, 0.32, 0.64 µg/ml -S9 20h: 0.1, 0.2, 0.3 µg/ml |
The test material was classified as “negative” for chromosomal aberrations, under the test conditions. Cell survival was reduced below 50 % in the highest evaluated concentrations. Higher dose levels were not evaluable because of an insufficient number of metaphases. |
Proprietary Aventis, 2003 PT03-0029 |
OECD 473, GLP CHL (V79) |
Chromosomal aberration |
+/- |
Duomeen OV Oleyl-diamine 92.3% In Ethanol |
+S9: 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.5 and 8.0 µg/mL -S9 4h: 0.2, 0.4, 0.55, 0.7, 0.85, 1.0 and 1.2 µg/mL -S9 20h: 0.05, 0.1, 0.2, 0.4, 0.55, 0.7, 0.85, 1.0 and 1.2 µg/mL |
The test material was classified as “negative” for chromosomal aberrations, under the test conditions. The lowest concentration producing cell toxicity was 4.0 mg/mL with metabolic activation and 1.0 (4h) and 0.4 (20h) mg/mL without metabolic activation. |
Proprietary BSL, 2008 081575 |
OECD 476, GLP CHL (V79) |
forward mutations (HPRT locus) |
+/- |
Duomeen OV Oleyl-diamine 92.3% In Ethanol |
+S9: 0.05, 0.10, 0.25, 0.5, 1.0, 2.0, 3.0, 3.8, 4.0, 4.2, 5.0, 5.5, 6.0, 7.0 µg/mL -S9 4h: 0.350, 0.425, 0.500, 0.575, 0.650, 0.725, 0.800, 0.875 µg/mL -S9 20h: 0.1, 0.2, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 µg/mL |
The test material was non-mutagenic in the HPRT locus using V79 cells of the Chinese hamster. Cytotoxicity was observed from 5.0 mg/mL with metabolic activation and 0.875 (4h) and 0.9 (20h) mg/mL without metabolic activation. |
Proprietary BSL, 2010 092013 |
Mammalian SystemsIn Vivo |
||||||
OECD474, GLP MouseSwiss Webster, adult, M and F |
MN induction |
na |
Duomeen C Coco-diamine, in corn oil |
Oral main study: 0, 31.3, 62.5 or 125 mg/kg/day; 5 animals/dose/sex + 125 mg additional 9 animals/sex |
Does not increase frequency in micronuclei in mouse bone marrow PCE. Toxicity: 65% suppression PCE/RBC ratio at 125 mg |
Proprietary. SRI, 1991 1924-C01-90 |
np = not provided; na = not applicable
References:
· Aventis, 2003: Aventis Pharma, PT03-0028, 27-06-2003, GENAMIN LAP 100 D bacterial reverse mutation test.
· Aventis, 2003: Aventis Pharma, PT03-0029, 16-07-2003, GENAMIN LAP 100 Din vitromammalian chromosome aberration test in V79 Chinese Hamster Cells.
· RCC Notox, 1990: RCC Notox, 031444,, Evaluation of the mutagenic activity of Duomeen C in the Ames Salmonella/microsome test (with independent repeat).
· SRI, 1991: SRI International, 1924-C01-90, 28-03-1991, Measurement of micronuclei in bone marrow erythrocytes of Swiss-Webster mice treated with Duomeen C.
· BSL, 2008: BSL Bioservice, 081561, 22-09-2008, Reverse mutation assay using bacteria Salmonella typhimurium and Escherichia coli with N-(Hydrogenated tallow)-1,3-diaminopropane.
· CIT, 1986: CIT, CIT, 2097 MMO, 21-05-1986, Dinoram SH - Study on the mutagenic properties in vitro in the Ames test.
· BSL, 2008: BSL Bioservice, 081576, 23-09-2008, Reverse mutation assay using bacteria Salmonella typhimurium and Escherichia coli with N-Oleyl-1,3-diaminopropane
· BSL, 2008: BSL Bioservice, 081575,, In vitro mammalian chromosome aberration test in Chinese hamster V79 cells with N-Oleyl.1,3.diaminopropane
· BSL, 2010: BSL Bioservice, 092013, 29-04-2010, In vitro mammalian cell gene mutation test (HPRT-locus) in Chinese hamster V79 cells with N-Oleyl.1,3-diaminopropane
Justification for classification or non-classification
Available studies show no concern for possible genotoxicity. Also further property data for Diamine C16-18, C18-unsaturated indicate that genotoxic properties are rather unlikely.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)